“The field has been optimizing an expensive, destructive tool, while the richer signal sits untouched on the slide in every pathology lab.”
— Victor Outters, CEO, HyprView
- October 15, 2026
- October 15, 2026
CEO Interview: HyprView
“The field has been optimizing an expensive, destructive tool, while the richer signal sits untouched on the slide in every pathology lab.”
— Victor Outters, CEO, HyprView